

| R&D No | REC No | Eudract | Research Title |
|-------------------|---------------|----------------|--|
| A091476 | 08/H0304/125 | 2008-006161-84 | ARTIST - Aromasin Randomised Trial +/- Sudent as neoadjuvant Therapy for post-menopausal women with breast cancer. |

CI Professor Helena Earl - 12/12/2016

The above study was stopped by the company (Pfizer) after only 1 patient had been entered. This was an investigator initiated study, sponsored by Cambridge UHFT and University of Cambridge, funded by Pfizer through an unrestricted educational grant.

The reason for Pfizer stopping the study temporarily and then permanently, was because a metastatic study in breast cancer had reported a negative end point. Pfizer were therefore not pursuing a licence for sudent in breast cancer, and halted the study.

No reports have therefore been prepared for this study.

Yours sincerely

Professor Helena Earl